Belgium's Amakem Raises €18 million In Europe's Largest Series A So Far In 2011
This article was originally published in The Pink Sheet Daily
Belgian start-up raises record-breaking €18 million A round to take rho kinase inhibitor glaucoma candidate to clinical proof-of-concept.
You may also be interested in...
Funding for private biotech companies in Europe declines 17% during 2011, while funding for public biotech companies falls 50%, although 2012 starts strongly.
Biopharma financing dropped in Q3 2011 to $1.3 billion, down from $6.3 billion in Q2. There were 20 M&A deals that totaled $30.9 billion, attributed mainly to the $27.7 million merger of PBMs Express Scripts and Medco. Almost a quarter of the alliances penned were for preclinical assets.
Oxford BioMedica and U.S. researchers at the Mayo Clinic are to use the company's lentivirus vector to deliver two prostaglandin-related genes into the front of the eye to alleviate glaucoma.